Market closed
ImmunityBio/$IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Ticker
$IBRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
680
Website
ImmunityBio Metrics
BasicAdvanced
$2.4B
-
-$0.62
-0.18
-
Price and volume
Market cap
$2.4B
Beta
-0.18
52-week high
$10.53
52-week low
$2.28
Average daily volume
6.8M
Financial strength
Current ratio
3.36
Quick ratio
2.775
Long term debt to equity
-160.02
Total debt to equity
-161.805
Interest coverage (TTM)
-2.23%
Management effectiveness
Return on assets (TTM)
-48.48%
Return on equity (TTM)
77.02%
Valuation
Price to revenue (TTM)
127.217
Price to book
-4.69
Price to tangible book (TTM)
-4.54
Price to free cash flow (TTM)
-4.712
Growth
Revenue change (TTM)
2,270.58%
Earnings per share change (TTM)
-46.19%
3-year revenue growth (CAGR)
150.86%
3-year earnings per share growth (CAGR)
-11.44%
What the Analysts think about ImmunityBio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
ImmunityBio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ImmunityBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ImmunityBio News
AllArticlesVideos
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
Business Wire·2 days ago
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
Business Wire·2 weeks ago
ImmunityBio: Taking Care Of Business
Seeking Alpha·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $2.4B as of April 24, 2025.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of April 24, 2025.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of April 24, 2025.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.18. This means that it has an inverse relation to market volatility.